1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma

Technology appraisal guidance [TA306] Published date: 26 February 2014

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • 8 Appraisal Committee members and NICE project team
  • 9 Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance
  • Save
  • Save as PDF
  • Save as ePub
  • Save as eBook

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

Details are correct at the time of publication. Further information is available on the NICE website.

  • Rituximab for aggressive non-Hodgkin's lymphoma. NICE technology appraisal guidance 65 (2003).

  • Improving outcomes in haematological cancers. NICE cancer service guidance (2003).

  • National Institute for Health and Care Excellence (NICE)

  • Next